Resonance Health Revenue Rises 42% to $15.8M

The ASX-listed healthcare technology company returned to profit in FY26 and issued FY27 revenue and EBITDA guidance.

Updated on Nov. 19, 2026 in Healthcare

A large cylindrical medical scanner bore set into a pale wall in a bare, sunlit clinical room with no people visible.
Resonance Health reported FY26 revenue of $15.8 million, up 42%, and returned to profit as demand for liver and obesity trial imaging rose. AI Illustration. Upload story photo >

Resonance Health Limited reported FY26 revenue of $15.8 million, a 42% increase, and a net profit after tax of $1.5 million after a prior-year net loss of $1.7 million. The company's clinical trial imaging revenue rose 88% and its CRO revenue grew 81%.

Why it matters

The results reflect rising demand for precise imaging in liver disease and obesity clinical trials across Australia's healthcare sector. Resonance Health also completed a $6 million placement in October 2026 to fund strategic programs.

Resonance Health reported FY26 revenue of $15.8 million, with imaging revenue from clinical trials up 88% and CRO revenue up 81%. FY27 normalised EBITDA guidance is $2.6 million to $3.6 million, and the guidance excludes the liver fibrosis device, future acquisitions and further geographic expansion.

The players

Resonance Health Limited

An Australian healthcare technology and services company listed on the ASX under the ticker RHT, operating across imaging, clinical and investigator site services.

The details

Resonance Health operates an integrated model spanning Resonance Imaging, Resonance Clinical and TrialsWest investigator sites. The company said growth was driven by rising liver disease, approved MASH therapies and a surge in GLP-1 and obesity clinical trials requiring precise imaging, and it plans to expand TrialsWest sites to Australia's east coast.

Timeline

  1. October 2026: Completed $6 million placement for strategic programs.

  2. FY26: Reported 42% revenue growth and return to profit.

  3. FY27: Revenue and EBITDA guidance issued.

  4. End of FY28: Targets $50 million in revenue, expected to include strategic acquisitions.

Health Landscape

Resonance Health's growth follows the clinical trial demand created by approved MASH therapies and the surge in GLP-1 and obesity drug research. The results show how imaging providers are benefiting from pharmaceutical pipelines that require precise liver and metabolic assessments.

For patients, growth in clinical trial imaging can expand access to studies for liver disease and obesity treatments. The company's expansion to Australia's east coast may bring investigator sites closer to participants outside major Western Australian centres.

The takeaway

Resonance Health's results show that specialised imaging for clinical trials is a growing segment of Australia's healthcare market. Investors and industry watchers should track whether its FY27 guidance and FY28 $50 million target are met.

Further reading

Explore more Healthcare coverage for context on the clinical trial and diagnostics market.

Source note: This article includes information reported by Finance News Network.